Repurposing antihypertensive drugs for pain disorders: a drug-target mendelian randomization study

被引:0
|
作者
Du, Kai [1 ]
Li, Ao [1 ]
Zhang, Chen-Yu [1 ]
Li, Shu-Ming [2 ]
Chen, Ping [2 ]
机构
[1] Beijing Univ Chinese Med, Grad Sch, Beijing, Peoples R China
[2] Capital Med Univ, Beijing Hosp Tradit Chinese Med, Dept Pain Med, Beijing, Peoples R China
关键词
antihypertensive drug; hypertension; pain management; drug target mendelian randomization; drug repurposing; GENE-RELATED PEPTIDE; PRETREATMENT; INJECTION; ASSOCIATION; INSTRUMENTS; PROVIDES; ESMOLOL; BIAS;
D O I
10.3389/fphar.2024.1448319
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Objective Addressing the rising prevalence of pain disorders and limitations of current analgesics, our study explores repurposing antihypertensive drugs for pain management, inspired by the link between hypertension and pain. We leverage a drug-target Mendelian Randomization (MR) approach to explore their dual benefits and establish causal connections.Methods A comprehensive compilation of antihypertensive drug classes was undertaken through British National Formulary, with their target genes identified using the DrugBank database. Relevant single nucleotide polymorphisms (SNPs) associated with these targets were selected from published genomic studies on systolic blood pressure (SBP) as genetic instruments. These SNPs were validated through MR against acute coronary artery disease (CAD) to ensure genes not linked to CAD were excluded from acting as proxies for antihypertensive drugs. An MR analysis of 29 pain-related outcomes was conducted using the FinnGen R10 database employing the selected and validated genetic instruments. We utilized the Inverse Variance Weighted (IVW) method for primary analysis, applying Bonferroni correction to control type I error. IVW's multiplicative random effects (MRE) addressed heterogeneity, and MR-PRESSO managed pleiotropy, ensuring accurate causal inference.Results Our analysis differentiates strong and suggestive evidence in linking antihypertensive drugs to pain disorder risks. Strong evidence was found for adrenergic neuron blockers increasing migraine without aura risk, loop diuretics reducing panniculitis, and vasodilator antihypertensives lowering limb pain risk. Suggestive evidence suggests alpha-adrenoceptor blockers might increase migraine risk, while beta-adrenoceptor blockers could lower radiculopathy risk. Adrenergic neuron blockers also show a potential protective effect against coxarthrosis (hip osteoarthritis) and increased femgenpain risk (pain and other conditions related to female genital organs and menstrual cycle). Additionally, suggestive links were found between vasodilator antihypertensives and reduced radiculopathy risk, and both alpha-adrenoceptor blockers and renin inhibitors possibly decreasing dorsalgianas risk (unspecified dorsalgia). These findings highlight the intricate effects of antihypertensive drugs on pain disorders, underlining the need for further research.Conclusion The findings indicate that antihypertensive medications may exert varied effects on pain management, suggesting a repurposing potential for treating specific pain disorders. The results advocate for further research to confirm these associations and to explore underlying mechanisms, to optimize pain management practices.
引用
收藏
页数:11
相关论文
共 50 条
  • [21] Exploring the causal effect between lipid-modifying drugs and idiopathic pulmonary fibrosis: a drug-target Mendelian randomization study
    Cai, Gexiang
    Liu, Jingjing
    Cai, Mengsi
    Shao, Lianyou
    LIPIDS IN HEALTH AND DISEASE, 2024, 23 (01)
  • [22] Genetically predicted blood pressure, antihypertensive drugs and risk of heart failure: a Mendelian randomization study
    Lian, Jiao
    Shi, Xuezhong
    Jia, Xiaocan
    Fan, Jingwen
    Wang, Yuping
    Zhao, Yang
    Yang, Yongli
    JOURNAL OF HYPERTENSION, 2023, 41 (01) : 44 - 50
  • [23] The effects of blood pressure and antihypertensive drugs on heart failure: A Mendelian randomization study
    Li, Yueying
    Xiao, Wendi
    Huang, Ninghao
    Zhuang, Zhenhuang
    Zhang, Linjing
    Wang, Wenxiu
    Song, Zimin
    Zhao, Yimin
    Dong, Xue
    Xu, Ming
    Huang, Tao
    NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES, 2023, 33 (07) : 1420 - 1428
  • [24] Causal relationship between genetic proxies for calcium channel blockers and the risk of depression: a drug-target Mendelian randomization study
    Ye, Chaoyi
    Wang, Tingjun
    Wang, Huajun
    Lian, Guili
    Xie, Liangdi
    FRONTIERS IN PSYCHIATRY, 2024, 15
  • [25] Comparing the Relationships of Genetically Proxied PCSK9 Inhibition With Mood Disorders, Cognition, and Dementia Between Men and Women: A Drug-Target Mendelian Randomization Study
    Bell, Andrew S.
    Rosoff, Daniel B.
    Mavromatis, Lucas A.
    Jung, Jeesun
    Wagner, Josephin
    Lohoff, Falk W.
    JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2022, 11 (21):
  • [26] New evidence: Metformin unsuitable as routine adjuvant for breast cancer: a drug-target mendelian randomization analysis
    Xu, Jing-Xuan
    Zhu, Qi-Long
    Bi, Yu-Miao
    Peng, Yu-Chong
    BMC CANCER, 2024, 24 (01)
  • [27] Assessing the safety of lipid-modifying medications among Chinese adolescents: a drug-target Mendelian randomization study
    Shan Luo
    Hugh Simon Lam
    Yap Hang Chan
    Clara Sze Man Tang
    Baoting He
    Man Ki Kwok
    Gabriel M. Leung
    C Mary Schooling
    Shiu Lun Au Yeung
    BMC Medicine, 21
  • [28] Assessing the safety of lipid-modifying medications among Chinese adolescents: a drug-target Mendelian randomization study
    Luo, Shan
    Lam, Hugh Simon
    Chan, Yap Hang
    Tang, Clara Sze Man
    He, Baoting
    Kwok, Man Ki
    Leung, Gabriel M.
    Schooling, C. Mary
    Au Yeung, Shiu Lun
    BMC MEDICINE, 2023, 21 (01)
  • [29] Genetically determined blood pressure, antihypertensive drug classes, and frailty: A Mendelian randomization study
    Zhuang, Zhenhuang
    Li, Yueying
    Zhao, Yimin
    Huang, Ninghao
    Wang, Wenxiu
    Xiao, Wendi
    Du, Jie
    Dong, Xue
    Song, Zimin
    Jia, Jinzhu
    Liu, Zhonghua
    Clarke, Robert
    Qi, Lu
    Huang, Tao
    AGING CELL, 2024, 23 (07)
  • [30] Utilizing genetics and proteomics to assess the role of antihypertensive drugs in human longevity and the underlying pathways: a Mendelian randomization study
    Fan, Bohan
    Zhao, Jie, V
    EUROPEAN HEART JOURNAL-CARDIOVASCULAR PHARMACOTHERAPY, 2024, 10 (06) : 537 - 546